Wuxi AppTec's Full-Year Profit Doubles, Stock Price Surges

LootboxPhobia · 2026-03-24T05:54:08+00:00

WuXi AppTec's stock price rose due to strong annual performance, with net profit attributable to shareholders projected to increase to 19.19 billion yuan. The company's revenue grew 15.8%, driven by strong core business and overseas demand. The future forecast projects revenue of 51.3 billion to 53 billion yuan by 2026, with a recommended cash dividend of 15.7927 yuan per 10 shares.

LootboxPhobia

2026-03-24 05:54:08

Abstract generation in progress

Investing.com - WuXi AppTec (SS:603259) stock rose on Tuesday after the Chinese pharmaceutical research and manufacturing service provider announced stronger annual results, driven by robust growth in its core chemical business and increased overseas demand.

The company said after Monday’s close that net profit attributable to shareholders for 2025 would more than double to 19.19 billion yuan ($2.79 billion).

WuXi’s Hong Kong-listed shares surged as much as 10% to HKD 112.8 on Tuesday, while Shanghai-listed shares climbed nearly 7% to CNY 93.65.

Get real-time stock trend updates with InvestingPro

Revenue increased 15.8% to CNY 45.46 billion, with WuXi Helai’s revenue soaring 25.5%.

Adjusted non-IFRS net profit grew 41.3% to CNY 14.96 billion, with gross margin rising from 40.8% a year earlier to 47.0%, reflecting stronger contributions from late-stage clinical and commercial projects.

Revenue from U.S. clients rose 34.3%, offsetting weak demand in Europe and China, while order backlog for ongoing operations increased 28.8% to CNY 58 billion by the end of 2025.

WuXi AppTec forecasts revenue for 2026 to be between CNY 51.3 billion and CNY 53 billion, representing an 18% to 22% growth in ongoing operations.

The company proposed a final cash dividend of CNY 15.7927 per 10 shares.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.